What is molnupiravir?

Molnupiravir
It is an oral capsule drug developed by an American pharmaceutical company (Merch&Co, MSD). Results of a phase 3 clinical trial in 2021 suggest it could reduce the risk of hospitalization or death from Covid-19 by about 30%.

Licenses for use in countries
Country Licenses In addition to the emergency use authorization of Molnupiravir (EUA) from the US Food and Drug Administration (FDA) by the end of 2021, a conditional marketing authorization has been issued. approved in the UK, and the European Medicines Agency (EMA) has also issued positive scientific advice in favor of emergency use in EU member states prior to marketing authorization.

Taiwan also adopted the EUA on January 13, 2022.
On February 17, 2022, the Drug Administration of Vietnam Ministry of Health issued an urgent dispatch to appoint Vietnamese companies to produce 3 drugs with Molnupiravir ingredients.

User object
Each course of treatment for 5 days, 12 hours apart take 2 tablets of 400mg, including 20 tablets.

Recommendation
For F0 (tested positive) use only. Not licensed to use to prevent Covid-19.
Not suitable for minors, may affect the development of bones and cartilage.
Pregnant women should not use it, it can harm the unborn baby.
If you are planning to become pregnant, adult men and women should use contraception for 3 months after treatment.

Side effects
Due to the limited clinical trial experience of Molnupiravir, all possible risks have not been fully determined at this time,
diarrhea, nausea, dizziness etc., or other serious and undesirable side effects may also occur..

Conclusion
Currently, Molnupiravir is only used for F0 (tested positive), for preventive use or for adolescents, pregnant women, and groups planning pregnancy should still use other drugs. More clinical trial information is still needed to finalize the drug's effectiveness and side effects.

Source